

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
3 February 2005 (03.02.2005)

PCT

(10) International Publication Number  
**WO 2005/009217 A2**

- (51) International Patent Classification<sup>7</sup>: **A61B**
- (21) International Application Number:  
PCT/US2004/023191
- (22) International Filing Date: 16 July 2004 (16.07.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
60/489,035 21 July 2003 (21.07.2003) US
- (71) Applicant (for all designated States except US): **MEDIMUNE, INC.** [US/US]; One MedImmune Way, Gaithersburg, MD 20878 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **KINCH, Michael, S.** [US/US]; 19627 Hoover Farm Drive, Laytonsville, MD 20882 (US).
- (74) Agents: **INSOGNA, Anthony, M. et al.**; Jones Day, 222 East 41st Street, New York, NY 10017-6702 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**  
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: **DIAGNOSIS OF PRE-CANCEROUS CONDITIONS USING PCDGF AGENTS**

(57) Abstract: The present invention relates to methods and compositions designed for the treatment or management of pre-cancerous conditions, especially in order to prevent, delay, or decrease the likelihood that the pre-cancerous condition will progress to malignant cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that decrease/inhibit PCDGF expression, secretion, and/or activity. The invention also provides pharmaceutical compositions comprising one or more PCDGF agents. In some embodiments, the PCDGF agents can be administered with other therapeutic agents for treatment or management of a pre-cancerous condition that are not PCDGF-based. Diagnostic methods and methods for screening for therapeutically useful PCDGF agents are also provided.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
3 February 2005 (03.02.2005)

PCT

(10) International Publication Number  
**WO 2005/009217 A3**

(51) International Patent Classification<sup>7</sup>: **A61K 38/00**,  
C07K 1/00, 2/00, 4/00, 5/00, 7/00, 14/00, 16/00, 17/00,  
C12Q 1/00

(21) International Application Number:  
PCT/US2004/023191

(22) International Filing Date: 16 July 2004 (16.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/489,035 21 July 2003 (21.07.2003) US

(71) Applicant (for all designated States except US): **MEDIM-  
MUNE, INC.** [US/US]; One MedImmune Way, Gaithers-  
burg, MD 20878 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): **KINCH, Michael, S.**  
[US/US]; 19627 Hoover Farm Drive, Laytonsville, MD  
20882 (US).

(74) Agents: **INSOGNA, Anthony, M.** et al.; Jones Day, 222  
East 41st Street, New York, NY 10017-6702 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,

AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,  
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,  
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,  
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,  
ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,  
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,  
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,  
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the  
claims and to be republished in the event of receipt of  
amendments

(88) Date of publication of the international search report:  
26 May 2005

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

(54) Title: **DIAGNOSIS OF PRE-CANCEROUS CONDITIONS USING PCDGF AGENTS**

(57) Abstract: The present invention relates to methods and compositions designed for the treatment or management of pre-can-  
cerous conditions, especially in order to prevent, delay, or decrease the likelihood that the pre-cancerous condition will progress  
to malignant cancer. The methods of the invention comprise the administration of an effective amount of one or more agents that  
decrease/inhibit PCDGF expression, secretion, and/or activity. The invention also provides pharmaceutical compositions compris-  
ing one or more PCDGF agents. In some embodiments, the PCDGF agents can be administered with other therapeutic agents for  
treatment or management of a pre-cancerous condition that are not PCDGF-based. Diagnostic methods and methods for screening  
for therapeutically useful PCDGF agents are also provided.



**WO 2005/009217 A3**